* If you want to update the article please login/register
Objectives: Primary aim: Objectives: The primary goal of each individual patient with metastatic radioiodine-avid thyroid cancer under surveillance with rhTSH and THW is to compare the 124I-PET/CT lesional and whole body dosimetry. Endpoints: Primary Endpoint: The estimated radiation dose was determined as rads per lesion in comparison to each measurable lesion under rhTSH and under THW.
Source link: https://clinicaltrials.gov/ct2/show/NCT03841617
Preclinically and in a few clinical cases, the latest development of quinoline-based PET tracers that function as FAP inhibitors showed promising results. Integrin u03b1vu00b23 is limited to expression of angiogenic blood vessels and tumor cells. The present research sought to determine the biodistribution, pharmacokinetics, and dosimetry of 68Ga-FAP-RGD's patients with various cancers, compared head-to-head with 68Ga-FAPI-02 or 18F-FDG PET/CT scans in patients with various cancers.
Source link: https://clinicaltrials.gov/ct2/show/NCT05515783
This report is a prospective, single-arm pilot trial aimed at patients with hemoptysis from lung cancers. Tc99m-MAA will be administered to the bronchial artery prior to bronchial artery embolization, and an imaging will be obtained to determine MAA distribution. To get a preliminary report of the potential for efficacy and predicted safety of Yittrium-90 bronchial artery radio-embolization, a non-statistical comparison will be made between literature-reported external-beam radiation dose-related tumor reaction and adjacent-organ toxicities.
Source link: https://clinicaltrials.gov/ct2/show/NCT04555564
In the initial testing and analysis of PCa's prognosis, conventional prostate cancer imaging techniques have limited success. A cell surface antigen is highly expressed in PCa and correlates with prognostic variables, such as Gleason's score. High PSMA levels in prostate tumors have been strongly related to lethality of disease, allowing for precise identification of tumors that require treatment. With one imaging technique, an additional benefit of PET over MRI is the ability to detect both distant metastatic disease and intraprostatic disease. The reason for focal therapy is based on the knowledge that whole gland therapy can result in unacceptable toxicity rates, but it is also known that patient morbidity and mortality are due to the onset of common foci of high-grade disease, i. e. The investigators have shown that a modest decrease in dose results in clinically meaningful reductions in urinary toxicity in a large cohort of patients treated at Johns Hopkins has resulted in clinically meaningful improvements in urinary toxicity. However, focal planning were extremely sensitive to seed positioning errors, and focal targeting made seed positioning more relevant. When compared to a historical group of patients, the iRUF Phase II cohort made statistically significant improvements in prostate coverage metrics, as well as lower rates of rectal doses exceeding prescribed tolerance limits. With a focal focus, this research will explore the possibility of PSMA-imaging with iRUF dynamic dosimetry to diagnose prostate cancer using a multi-phase approach.
Source link: https://clinicaltrials.gov/ct2/show/NCT03861676
Approximately 80 patients will be enrolled in the study, 20 patients with GBM, 20 patients with BC that has metastasized to the brain, 20 with GEA, and 20 with PDAC. On Day 1 as well as conventional imaging, all patients enrolled in the study will receive a single dose of [68Ga]-FF58 and undergo [68Ga]-FF58 PET imaging at various timepoints as well as traditional imaging.
Source link: https://clinicaltrials.gov/ct2/show/NCT04712721
The screening period is followed by the medical period, followed by the prescription period, and the follow-up period is included in the study schedule for each patient. On Week 1 of each cycle, the Lutathera administration will begin. Each patient will receive a total of four doses of Lutathera. According to the approved Lutathera local prescribing data, an infusion of 2. 5% Lysine - Arginine amino acid solution would be co-administered with each Lutathera dose for renal protection. An antiemetic will be given before infusion of the AA drug for the prevention of infusion-related nausea and vomiting. Each patient's clinical treatment period came one time during the study treatment period. The dosimetry report will allow for estimation from the 1st Lutt Lutathera administration of cumulative absorbed radiation doses from 4 Lutathera doses as well as a decision on the next dose levels. An accelerated review of dosimetry and safety data for each patient in the study will be done in order to enable the Investigator to make a decision regarding the subsequent Luttathera doses in order to minimize risks for each study subject. For every patient who received at least one dose of Lutathera, a complete follow-up period of five years will occur. An external Data and Safety Monitoring Board would also participate in the study to analyze growing safety and dosimetry data to ensure the wellbeing of adolescents participating in the study, as well as the clinical team in charge of the study.
Source link: https://clinicaltrials.gov/ct2/show/NCT04711135
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions